Roche Holding AG's EBIT per Share for the
six
months ended in Dec. 2025 was CHF10.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF22.81.
During the past 12 months, the average EBIT per Share Growth Rate of Roche Holding AG was 37.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 2.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -1.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 2.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Roche Holding AG's EBIT per Share or its related term are showing as below:
XSWX:RO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -38.2 Med: 2.1 Max: 80.7
Current: 2.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Roche Holding AG was 80.70% per year. The lowest was -38.20% per year. And the median was 2.10% per year.
XSWX:RO's 3-Year EBIT Growth Rate is ranked worse than 59.83% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs XSWX:RO: 2.10
Roche Holding AG (XSWX:RO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Roche Holding AG EBIT per Share Related Terms
Roche Holding AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF22.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:RO) has a EBIT per Share of CHF22.81 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Roche Holding AG and its competitors. According to the industry distribution chart, Roche Holding AG ranks #484 out of 809 companies in the Drug Manufacturers industry, placing it in the top 59.8%.
Is Roche Holding AG's EBIT per Share too high?
Roche Holding AG's current EBIT per Share is CHF22.81. Based on the distribution chart, Roche Holding AG ranks #484 out of 809 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #484 out of 809 companies for EBIT per Share. This places Roche Holding AG in the lower half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current EBIT per Share is CHF22.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF269.33, compared to a current price of CHF342.00 — trading 27% above its estimated fair value. The current EBIT per Share is CHF22.81. Roche Holding AG's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current EBIT per Share is CHF22.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF342.00 is trading 27% above its estimated GF Value™ of CHF269.33.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:RO:
EBIT per Share: CHF22.81
GF Value™: CHF269.33 vs. price of CHF342.00 (27% above fair value)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
78GF Score
Get the complete analysis for XSWX:RO
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
